Palmitoylethanolamide (PEA, Ultra-Fine Powder 5Micron)
amide (amide) of fatty acids within the body It has been shown to bind to receptors in the cell nucleus. which is a receptor that activates the peroxisome proliferator and acts to reduce pain and chronic inflammation
Palmitoylethanolamide (PEA) amide (amide) of fatty acids within the body. It has been shown to bind to receptors in the cell nucleus. It is a receptor that activates the peroxisome proliferator and acts to reduce pain and chronic inflammation.
PEA has been shown in clinical trials to help reduce the severity of peripheral neuropathy such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, osteoarthritis pain, low back pain, and chemotherapy. Postoperative pain, toothache, neuropathic pain in stroke and sclerosis, chronic pelvic pain.
It is now used as an ingredient in dietary supplements. many countries
The Food and Drug Administration (FDA) of Thailand has not yet allowed its use in dietary supplements.
this item Sold for research purposes only, not for human use.
- Room (25-40C)
- 24 Months from manufacturing or testing date.
- › NOT contain Egg
- 300mg - 600mg
- 500mg
- 300mg - 600mg
- 500mg
- Add into oil phase. Heat tolerant.
- Avoid heat above 70C
- 4.00 - 5.50
- Dispersible in water, Soluble in DMSO (Dimethyl Sulfoxide), Soluble in Organic Solvents
- -
| Test Name | Specification |
|---|---|
| Appearance | White micro powder |
| Assay (% on dry basis) | 98-102% |
| Loss on drying | 1.0% Max |
| Residue on ignition | 0.1% Max |
| Particle Size (5 Micron) | D(0.80-1.00) |
| Residue solvent: Methanol | 3000ppm Max |
| Residue solvent: Ethanol | 5000ppm Max |
| Arsenic | 1ppm Max |
| Cadmium | 2.5ppm Max |
| Lead | 0.5ppm Max |
| Mercury | 1.5ppm Max |
| Total plate count | 1000CFU/g Max |
| Yeast & Mold | 100CFU/g Max |
| Coliforms | 0.92MPN/g Max |
| E.Coli | Negative |
| Salmonella sp. | Negative |
| Staphylococcus aureus | Negative |
| Pseudomonas aeruginosa | Negative |
Cart
No products